Data from the pivotal trial also showed that the safety profile of Kisqali at the 400mg dose was well-tolerated, with generally low-grade symptomatic adverse events. The European Commission (EC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback